Toward a Muscarinic Agent Solution for the Presynaptic Dopamine Problem in Schizophrenia
Research on Cobenfy (xanomeline-trospium) presents a novel approach to management of schizophrenia by targeting muscarinic acetylcholine receptors. By…
Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia
